Development of anti-TNF therapy for rheumatoid arthritis.

Development of anti-TNF therapy for rheumatoid arthritis.

The aetiology of systemic, autoimmune, chronic inflammatory diseases--such as rheumatoid arthritis--is not known, and their pathogenesis is complex and multifactorial. However, progress in the characterization of intercellular mediators--proteins that are now known as cytokines--has led to the reali...

Bibliografski detalji
Glavni autor:	Feldmann, M
Format:	Journal article
Jezik:	English
Izdano:	2002

Slični predmeti

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
od: Feldmann, M, i dr.
Izdano: (2011)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
od: Maini, R, i dr.
Izdano: (1993)

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
od: Taylor, P, i dr.
Izdano: (2009)

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
od: Feldmann, M, i dr.
Izdano: (2001)

Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy.
od: Maini, R, i dr.
Izdano: (2000)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
od: Maini, R, i dr.
Izdano: (1994)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
od: Maini, R, i dr.
Izdano: (1997)

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
od: Feldmann, M, i dr.
Izdano: (2004)

Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases.
od: Taylor, P
Izdano: (2001)

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
od: Ding, T, i dr.
Izdano: (2010)

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.
od: Taylor, P, i dr.
Izdano: (2000)

Influence on Effectiveness of Early Treatment with Anti-TNF Therapy in Rheumatoid Arthritis
od: Vicente Escudero-Vilaplana, i dr.
Izdano: (2012-05-01)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
od: Feldmann, M, i dr.
Izdano: (1995)

TNFα - A pivotal role in rheumatoid arthritis?
od: Brennan, F, i dr.
Izdano: (1992)

TNF alpha--a pivotal role in rheumatoid arthritis?
od: Brennan, F, i dr.
Izdano: (1992)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
od: Feldmann, M, i dr.
Izdano: (2001)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
od: Feldmann, M, i dr.
Izdano: (1995)

TNF alpha as a therapeutic target in rheumatoid arthritis.
od: Feldmann, M, i dr.
Izdano: (1994)

Gene expression profiling of treatment response to anti-TNF-alpha therapy in rheumatoid arthritis
od: Meisel, C, i dr.
Izdano: (2004)

Does bursitis of the forefoot improve in patients with rheumatoid arthritis on anti-TNF-alpha therapy?
od: Bowen, C, i dr.
Izdano: (2007)

Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti-TNF therapy.
od: Bowen, C, i dr.
Izdano: (2010)

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
od: Charles, P, i dr.
Izdano: (1999)

The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target.
od: Feldmann, M
Izdano: (1996)

Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy
od: Valentina Cestelli, i dr.
Izdano: (2014-01-01)

Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti-TNF therapy
od: Dewbury Keith, i dr.
Izdano: (2010-06-01)

Anti-TNF therapy improves hand function in rheumatoid arthritis within 3 months
od: Hull, D, i dr.
Izdano: (2012)

Anti-TNF therapy
od: Udalova, I, i dr.
Izdano: (2016)

Gene therapy for rheumatoid arthritis?
od: Feldmann, M
Izdano: (2001)

TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
od: Feldmann, M, i dr.
Izdano: (2003)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
od: Martin J. Bergman, i dr.
Izdano: (2020-08-01)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
od: Feldmann, M, i dr.
Izdano: (1997)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
od: Taylor, P, i dr.
Izdano: (2022)

Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis
od: Dorota Sikorska, i dr.
Izdano: (2018-10-01)

The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis
od: Madha Mohammed Sheet, i dr.
Izdano: (2014-06-01)

TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action
od: Elliott, M, i dr.
Izdano: (1995)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
od: Elliott, M, i dr.
Izdano: (1995)

Cytokine therapy in rheumatoid arthritis.
od: Maini, R, i dr.
Izdano: (1996)

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.
od: Feldmann, M, i dr.
Izdano: (2002)

Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: Preclinical and clinical studies
od: Feldmann, M, i dr.
Izdano: (2002)

Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.
od: Williams, R, i dr.
Izdano: (2000)